Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oral Contraceptives Petition Seeking Ban On Third-Generation Products Denied By FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Public Citizen losses again as the agency says current product labeling for desogestrel-containing oral contraceptives adequately describes the risk of venous thromboembolism; FDA notes the difficulty in comparing the magnitude of risks between combination OCs.

You may also be interested in...



EMA Moves To Reassure Europe Over Combined Contraceptives

EMA says there is currently no cause for concern, amid increasing claims in Europe’s media that combined contraceptives can cause blood clots.

Blood Clot Risk Of Drospirenone Products Remains Open Issue For FDA

Bayer updates labeling for its drospirenone-containing contraceptives to reflect potentially higher risks compared to other birth control pills as FDA seeks ways to get more definitive information.

Contraceptive Compliance Studies May Be Key To Assessing Risk Of Ortho Evra Patch

Some patients in an FDA-funded study had less risk for blood clots than others and finding the reason is a subject for future studies, several members of an advisory panel told FDA Dec. 9. The Reproductive Health Drugs and Drug Safety and Risk Management Committees concluded in a 19-5 vote that the drug’s benefits outweigh its risks.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel